Barbara Pro MD

Dr. Pro is a clinician, researcher and Professor of Medicine at Columbia University, Irving Medical Center, in the Division of Hematology and Oncology, and the Director of the Lymphoma program. Throughout her career she has focused on developing new and improved therapies for patients with B cell and T-cell lymphoproliferative disorders and have served as the PI on numerous clinical trials, including 4 trials that led to FDA approval of novel agents for the improved treatment of patients with these diseases (described below). This work has led to more than 150 peer-reviewed research articles in highly respected journals such as the Journal of Clinical Oncology, Blood, and Lancet. She also served as Chief of the Lymphoma Section and Founding Director of the Multidisciplinary CTCL program at the Kimmel Cancer Center at Thomas Jefferson University. She served on the NCCN guidelines panel for T-cell lymphoma and PCBCL and the ECOG Lymphoma Core Committee, among others. She is an editor for the journals Frontiers Oncology, and Clinical lymphoma, Myeloma, and Leukemia and serve as a reviewer for multiple journals, including Blood, Clinical Cancer Research and Leukemia and Lymphoma, as well as an abstract reviewer for the ASH and Society of Hematology annual meetings.